Humana Posts New, Revised Medical Coverage Policies

August 2019 ~

Humana has released its most recent medical coverage policy changes, including one new policy and updates to its brachytherapy, genetic testing, and transcatheter valve procedures policies.

According to the insurer, Humana’s medical and pharmacy coverage policies are based on evidence published in peer-reviewed medical literature, technology assessments obtained from independent medical research organizations, evidence-based consensus statements and evidence-based guidelines from nationally recognized professional healthcare organizations.

Humana’s most recent changes to medical and pharmacy coverage policies are as follows.

New Medical Coverage Policies

  • Karyotyping for Diagnosis of Noncancer Indications

Policies with Significant Revisions

  • Achalasia and Gastroesophageal Reflux Disease (GERD) Treatments
  • Brachytherapy
  • Breast Reconstruction
  • Comparative Genomic Hybridization/Chromosomal Microarray Analysis
  • Electrical Stimulation (ES) and Electromagnetic Therapy for the Treatment of Wounds
  • Genetic Testing for Diagnosis and Monitoring of Noncancer Indications
  • Genetic Testing for Ehlers Danlos Syndrome
  • Infertility Evaluation and Treatments
  • Keratoconus Surgical Treatments
  • Rhinoplasty/Septoplasty
  • Speech Generating Devices, Voice Prosthesis
  • Transcatheter Valve Procedures

Retired Policies

  • Electroconvulsive Therapy (ECT)

 

Full details on the medical and pharmacy coverage policy changes can be found on Humana’s Medical and Pharmacy Coverage Policies page.

 

 

Source(s): Humana’s YourPractice;

 

 

AdvantEdge